Who
Thomas Cahill
Director
Company insider
Files Form 4 as: Director, Prime Medicine.
In numbers
- Trades disclosed
- 13
- Buys
- 1
- Sells
- 0
- Bought
- $6.8M
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 24 Oct 2022
- Last trade
- 5 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 8 Jun 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 5 Jun 2026filed 8 Jun 2026 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —75,000 at $0.00 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —39,062 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,062 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code D | —45,000 | filing |
| 1 Aug 2025filed 5 Aug 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 | filing |
| 4 Jun 2025filed 5 Jun 2025 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 12 Jun 2024filed 14 Jun 2024 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 14 Jun 2023filed 16 Jun 2023 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,062 at $0.00 | filing |
| 24 Oct 2022filed 26 Oct 2022 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code C | —9,999,999 at $0.00 | filing |
| 24 Oct 2022filed 26 Oct 2022 | PRME Prime Medicineoption or derivative · Biotechnology | SEC FORM 4 Code C | —5,250,781 at $0.00 | filing |
| 24 Oct 2022filed 26 Oct 2022 | PRME Prime MedicineBiotechnology | SEC FORM 4 Code C | —4,905,679 | filing |
| 24 Oct 2022filed 26 Oct 2022 | PRME Prime MedicineBiotechnology | SEC FORM 4 Bought | $6.8M400,000 at $17.00 | filing |
News
No headline names them, or the companies they trade most, lately.